Comparative Pharmacology
Head-to-head clinical analysis: TYLOX versus TYMTRAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TYLOX versus TYMTRAN.
TYLOX vs TYMTRAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tylox combines oxycodone, a mu-opioid receptor agonist, with acetaminophen, which inhibits cyclooxygenase (COX) and modulates descending serotonergic pathways.
TYMTRAN (pegvorhyaluronidase alfa) is a recombinant human hyaluronidase that degrades hyaluronic acid (HA) in the tumor microenvironment, reducing interstitial fluid pressure and improving drug penetration.
1-2 capsules (oxycodone 5 mg/acetaminophen 325 mg) orally every 6 hours as needed for pain; maximum 12 capsules per day.
Intramuscular injection: 0.5 mg/kg body weight (maximum 25 mg per dose) administered once daily for 2 to 3 days. Oral: Not available.
None Documented
None Documented
Oxycodone: 3.5-5.6 hours; acetaminophen: 2-3 hours. In hepatic impairment, oxycodone half-life prolonged up to 13 hours.
Terminal elimination half-life is 12-15 hours in healthy adults, allowing twice-daily dosing; extended to 20-25 hours in hepatic impairment.
Renal: oxycodone ~19% unchanged; acetaminophen ~2-5% unchanged. Biliary: minimal. Fecal: <5% total. Total renal elimination: ~60-70% as metabolites of oxycodone (noroxycodone, oxymorphone) and acetaminophen conjugates.
Primarily hepatic metabolism via CYP3A4, with 70% excreted in feces as metabolites and 20% in urine as unchanged drug and metabolites.
Category C
Category C
Opioid analgesic combination
Opioid analgesic combination